Last reviewed · How we verify
Apremilast Modified Release 13
Apremilast is a small molecule inhibitor of phosphodiesterase 4 (PDE4), which leads to increased intracellular levels of cyclic adenosine monophosphate (cAMP).
Apremilast is a small molecule inhibitor of phosphodiesterase 4 (PDE4), which leads to increased intracellular levels of cyclic adenosine monophosphate (cAMP). Used for Plaque psoriasis, Psoriatic arthritis.
At a glance
| Generic name | Apremilast Modified Release 13 |
|---|---|
| Sponsor | Amgen |
| Drug class | PDE4 inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 1 |
Mechanism of action
By inhibiting PDE4, apremilast reduces the production of pro-inflammatory mediators and increases the production of anti-inflammatory mediators, thereby modulating the immune response and reducing inflammation.
Approved indications
- Plaque psoriasis
- Psoriatic arthritis
Common side effects
- Diarrhea
- Nausea
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apremilast Modified Release 13 CI brief — competitive landscape report
- Apremilast Modified Release 13 updates RSS · CI watch RSS
- Amgen portfolio CI